Ovarian Cancer | Topics

 
R Tyler Hillman, MD, PhD, on Important Contributors Needed to Treat Ovarian Granulosa Cell Tumors
June 18, 2021

An expert emphasizes how a big team is needed to properly employ the different therapeutic modalities needed to treat patients with ovarian granulosa cell tumors.

No Difference in Survival Noted With Longer Duration of Bevacizumab for Ovarian Cancer
June 07, 2021

Doubling treatment duration of bevacizumab did not lead to better survival in patients with ovarian cancer who were treated on a phase 3 trial.

Platinum-Agnostic Ovarian Cancer in Recurrent Setting May Benefit from Mirvetuximab Soravtansine/Bevacizumab
June 07, 2021

Results reported at the 2021 ASCO Annual Meeting show that half of patients treated in the FORWARD II trial achieved a response to therapy with mirvetuximab soravtansine and bevacizumab.